|
Number (%)
|
46 (26.7)
|
126 (73.3)
| |
|
Pneumonia onset, mean (SD), days
|
8.2 (5.1)
|
7.7 (3.7)
|
0.47
|
|
Sociodemographic variables
|
|
Age, mean (SD), years
|
53.7 (16.6)
|
63.0 (16.6)
| |
|
Sex, n (%)
|
|
Female
|
28 (60.9)
|
59 (46.8)
|
0.10
|
|
Male
|
18 (39.1)
|
67 (53.2)
|
0.10
|
|
Comorbidities
|
|
Cardiovascular risk factor
|
|
Smoke habit, n (%)
|
4 (8.7)
|
9 (7.1)
|
0.38
|
|
BMI ≥ 25 kg/m2, n (%)
|
20 (43.5)
|
70 (55.6)
|
0.25
|
|
Hypertension, n (%)
|
16 (34.8)
|
67 (53.2)
|
0.033
|
|
type 2 Diabetes, n (%)
|
4 (8.7)
|
29 (23.0)
|
0.035
|
|
Dyslipidemia, n (%)
|
15 (32.6)
|
53 (42.1)
|
0.26
|
|
Respiratory diseases
|
|
Asthma, n (%)
|
4 (8.7)
|
17 (13.5)
|
0.40
|
|
COPD, n (%)
|
3 (6.5)
|
6 (4.8)
|
0.65
|
|
Cardiovascular diseases
|
|
Ischaemic heart diseases, n (%)
|
1 (2.2)
|
8 (6.3)
|
0.28
|
|
Arrhythmias, n (%)
|
1 (2.2)
|
9 (7.1)
|
0.22
|
|
Heart failure, n (%)
|
2 (4.3)
|
5 (4.0)
|
0.91
|
|
Other diseases
|
|
Chronic kidney diseases, n (%)
|
0 (0.0)
|
12 (9.5)
|
0.030
|
|
Cognitive impairment, n (%)
|
3 (6.5)
|
7 (5.6)
|
0.81
|
|
Cancer, n (%)
|
1 (2.2)
|
9 (7.1)
|
0.22
|
|
Rheumatological diseases, n (%)
|
2 (4.3)
|
12 (9.5)
|
0.27
|
|
Chronic treatment
|
|
no drugs, n (%)
|
8 (17.4)
|
25 (19.8)
|
0.60
|
|
1–4 drugs, n (%)
|
21 (45.7)
|
47 (37.3)
| |
|
5–9 drugs, n (%)
|
12 (26.1)
|
31 (24.6)
| |
|
≥ 10 drugs, n (%)
|
5 (10.9)
|
23 (18.3)
| |
|
Antithrombotic/anticoagulant treatment
|
|
Antithrombotic drug, n (%)
|
1 (2.2)
|
13 (10.3)
|
0.22
|
|
Anticoagulant drug, n (%)
|
2 (4.3)
|
6 (4.8)
| |
|
Non consumption, n (%)
|
43 (93.5)
|
107 (84.9)
| |
|
Symptoms
|
|
Fever, n (%)
|
38 (82.6)
|
106 (84.1)
|
0.81
|
|
Cough, n (%)
|
37 (80.4)
|
103 (81.7)
|
0.84
|
|
Dyspnea, n (%)
|
24 (52.2)
|
79 (62.7)
|
0.21
|
|
Gastrointestinal disturbances, n(%)
|
18 (39.1)
|
54(42.9)
|
0.66
|
|
Myalgias, n (%)
|
17 (37.0)
|
34 (27.0)
|
0.20
|
|
Thoracic Pain, n (%)
|
10 (21.7)
|
17 (13.5)
|
0.19
|
|
Pleural chest Pain, n (%)
|
6 (13.0)
|
4 (3.2)
|
0.014
|
|
Rhinitis, n (%)
|
4 (8.7)
|
4 (3.2)
|
0.13
|
|
Odynophagia, n (%)
|
7 (15.2)
|
13 (10.3)
|
0.37
|
|
Asthenia, n (%)
|
12 (26.1)
|
35 (27.8)
|
0.83
|
|
Headache, n (%)
|
12 (26.1)
|
35 (27.8)
|
0.83
|
|
Dysgeusia, n (%)
|
3 (6.5)
|
6 (4.8)
|
0.65
|
|
Anosmia, n (%)
|
1 (2.2)
|
1 (0.8)
|
0.45
|
|
Symptoms categorized
|
|
1–3 total symptoms, n (%)
|
25 (54.3)
|
72 (57.6)
|
0.70
|
|
≥ 4 total symptoms, n (%)
|
21 (45.7)
|
53 (42.4)
| |
|
Physical examination
|
|
Temperature, mean (SD), ºC
|
37.2 (0.8)
|
37.3 (0.8)
|
0.86
|
|
Heart rate, mean (SD), bpm
|
96.2 (15.1)
|
92.2 (16.4)
|
0.20
|
|
Respiratory rate, median (IQR), rpm
|
16.0 (14.0, 16.0)
|
17.0 (15.0, 22.0)
|
0.073
|
|
Pulse oximetry, median (IQR), %
|
96.0 (94.0, 97.0)
|
94.0 (91.0, 96.0)
|
< 0.001
|
|
Normal lung auscultation, n (%)
|
16 (34.8)
|
22 (17.5)
|
0.014
|
|
Abnormal lung auscultation, n (%)
|
8 (17.4)
|
46 (36.5)
|
0.014
|
|
Blood test
|
|
CRP, median (IQR), mg/L
|
29.6 (5.0, 81.5)
|
81.5 (46.2, 143.0)
|
< 0.001
|
|
Lymphocytes, median (IQR), 10e3/ml
|
1400.0 (1100.0, 1880.0)
|
1000.0 (800.0, 1400.0)
|
< 0.001
|
|
D-Dimer, median (IQR), μg/L
|
339.0 (197.0, 464.0)
|
520.0 (320.0, 1030.0)
|
0.035
|
|
Fibrinogen ≥ 500, n (%), mg/dL
|
24 (52.2)
|
103 (81.7)
|
< 0.001
|
|
Ferritin, median (IQR), μg/L
|
618.0 (280.5, 919.0)
|
424.0 (200.0, 1215.0)
|
0.96
|
|
RT-PCR SARS-CoV-2
|
|
Negative, n (%)
|
17 (37.0)
|
19 (15.1)
|
0.006
|
|
Positive, n (%)
|
25 (54.3)
|
97 (77.0)
| |
|
Complications
|
|
Hospital admission, n (%)
|
20 (43.5)
|
120 (95.2)
|
< 0.001
|
|
Pulmonary thromboembolism, n (%)
|
0 (0.0)
|
7 (5.6)
|
0.10
|
|
Death, n (%)
|
1 (2.2)
|
10 (7.9)
|
0.17
|
